An interventional study of Conduction System Pacing and Conventional Right Ventricular Pacing in Atrioventricular Block, sponsored by Sheba Medical Center. Not yet recruiting at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Sheba Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study compares two ways of pacing the heart in adults with atrioventricular block, a condition in which electrical signals do not pass normally from the upper to the lower heart chambers. Participants must need a permanent pacemaker and have a left ventricular ejection fraction of at least 50% before implantation. Ejection fraction measures how much blood the main pumping chamber ejects with each beat.
The study will include 150 participants at Sheba Medical Center. By chance, 50 participants will receive conduction system pacing, which aims to stimulate the heart through its natural electrical conduction system, and 100 will receive conventional right ventricular pacing. Participants and treating clinicians will know which treatment is used.
The main question is whether the two pacing strategies differ in heart pumping function 24 months after implantation, taking the starting measurement into account. Researchers will also compare quality of life, heart-related emergency visits and hospitalizations, complications, pacemaker and lead function, repeat procedures, and use of healthcare resources.
Heart pumping function will be measured before implantation and at 12 and 24 months. Participants will complete the AQUAREL quality-of-life questionnaire before implantation and at 12, 24, 36, 48, and 60 months. Device follow-up will include routine clinical care and remote monitoring.
Outcomes Over Devices is a prospective, randomized, open-label, two-arm, single-center study comparing conduction system pacing (CSP) with conventional right ventricular pacing (RVP). The clinical indication for permanent pacing is established before recruitment. Randomization is 1:2 (50 CSP; 100 RVP), using a concealed computer-generated sequence with variable block sizes, stratified by baseline left ventricular ejection fraction (LVEF) of 50-59% versus at least 60%, without fixed quotas per stratum.
The primary analysis follows the intention-to-treat principle. The primary estimand is the between-arm difference in LVEF at 24 months, adjusted for baseline LVEF and stratification factors as appropriate. Post-baseline measurements at 12 and 24 months will be analyzed using a repeated-measures model with treatment arm, time, and their interaction. The 12-month evaluation is exploratory. The three AQUAREL domains will be scored and analyzed separately, with baseline adjustment and multiplicity addressed for the secondary 24-month comparisons. Detailed modeling and sensitivity analyses will be prespecified in the statistical analysis plan before unblinded comparative analyses.
Failure to achieve the allocated pacing strategy will not itself exclude a participant. Alternative pacing may be used when clinically necessary, with reasons and actual treatment documented; original allocation remains the basis for intention-to-treat analysis where possible. Actual ventricular pacing burden will be recorded and evaluated in prespecified secondary analyses. An independent Clinical Events Adjudication Committee will review prespecified clinical and device-related events, with arm masking where feasible.
The study is initiated by Sheba Medical Center. Medtronic does not fund the study; CSP systems are purchased under a discounted commercial arrangement. A separate, potentially outcome-based commercial reconciliation after 12 months does not determine clinical treatment or alter randomization, follow-up, data collection, analysis, or publication independence.
118 studies on the registry are indexed under Atrioventricular Block; 44 are open to participants now.
This study's planned enrollment of 150 is above the median of 130 across 79 interventional studies indexed under Atrioventricular Block.
Browse Atrioventricular Block studies →Sheba Medical Center is the lead sponsor of 680 studies on the registry; 65 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
50 participants allocated to conduction system pacing using a Medtronic SelectSecure MRI SureScan Model 3830 lead placed at the His bundle or left bundle branch area. Final lead position and programming are determined by the implanting electrophysiologist according to anatomy, electrical measurements, and clinical judgment.
Device: Conduction System Pacing
100 participants allocated to conventional right ventricular pacing using a standard pacing lead and conventional right ventricular lead position, according to usual clinical practice at the study center. Other medical treatment and device programming are determined by clinical need.
Device: Conventional Right Ventricular Pacing
Permanent pacing using a Medtronic SelectSecure MRI SureScan Model 3830 lead targeting His-bundle or left bundle branch area pacing. Final lead placement, fixation, and programming follow electrophysiological measurements and clinical judgment. Where feasible, the same pacemaker generator platform is used in both study arms.
Permanent pacemaker implantation with a conventional right ventricular pacing lead placed at a standard right ventricular site according to usual clinical practice at Sheba Medical Center. Device programming and accompanying medical treatment are determined by clinical need.
Left Ventricular Ejection Fraction at 24 Months
Left ventricular ejection fraction (LVEF), expressed as a percentage and measured by echocardiography at 24 months after implantation. The primary comparison is the between-arm difference adjusted for baseline LVEF and stratification factors as appropriate. The primary analysis follows the intention-to-treat principle.
Time frame: 24 months after pacemaker implantation.
Change From Baseline in AQUAREL Chest Discomfort Domain Score
Change from baseline in the AQUAREL chest discomfort domain, scored separately using the original algorithm. Domain scores range from 0 to 100; higher scores indicate better quality of life and positive changes indicate improvement. The secondary between-arm comparison at 24 months is adjusted for baseline domain score, with multiplicity addressed across the three domains. The 12-month analysis is exploratory; longer-term scores are also collected.
Time frame: Before pacemaker implantation (baseline) and at 12, 24, 36, 48, and 60 months after implantation.
Change From Baseline in AQUAREL Arrhythmia Domain Score
Change from baseline in the AQUAREL arrhythmia domain, scored separately using the original algorithm. Domain scores range from 0 to 100; higher scores indicate better quality of life and positive changes indicate improvement. The secondary between-arm comparison at 24 months is adjusted for baseline domain score, with multiplicity addressed across the three domains. The 12-month analysis is exploratory; longer-term scores are also collected.
Time frame: Before pacemaker implantation (baseline) and at 12, 24, 36, 48, and 60 months after implantation.
Change From Baseline in AQUAREL Exertional Dyspnea Domain Score
Change from baseline in the AQUAREL exertional dyspnea domain, scored separately using the original algorithm. Domain scores range from 0 to 100; higher scores indicate better quality of life and positive changes indicate improvement. The secondary between-arm comparison at 24 months is adjusted for baseline domain score, with multiplicity addressed across the three domains. The 12-month analysis is exploratory; longer-term scores are also collected.
Time frame: Before pacemaker implantation (baseline) and at 12, 24, 36, 48, and 60 months after implantation.
Ventricular Pacing Burden
Percentage of ventricular beats paced, obtained from device interrogation. Actual pacing burden is an explanatory secondary variable and is not a randomization criterion.
Time frame: Day 1 At pacemaker implantation and at 6, 12, and 24 months after implantation.
Ventricular Pacing Capture Threshold
Ventricular capture threshold, expressed in volts, measured during device interrogation. Measurements are recorded with the corresponding device settings to assess pacing performance over follow-up.
Time frame: Day 1 At pacemaker implantation and at 6, 12, and 24 months after implantation.
Ventricular Sensing Amplitude
Amplitude of sensed ventricular signals, expressed in millivolts, measured during device interrogation to assess lead and device performance over follow-up.
Time frame: Day 1 At pacemaker implantation and at 6, 12, and 24 months after implantation.
Cardiac or Pacing/Procedure-Related Emergency Department Visits
Number of emergency department visits related to cardiac disease, pacing, or the implantation procedure. Relevant events will be reviewed by the Clinical Events Adjudication Committee under definitions established before enrollment.
Time frame: From pacemaker implantation through 24 months after implantation (cumulative event count).
Cardiac or Pacing/Procedure-Related Hospitalizations
Number of hospital admissions related to cardiac disease, pacing, or the implantation procedure. Relevant events will be reviewed by the Clinical Events Adjudication Committee under definitions established before enrollment.
Time frame: From pacemaker implantation through 24 months after implantation (cumulative event count).
Heart Failure Events
Number of heart failure events during follow-up, reviewed by the Clinical Events Adjudication Committee. Written event definitions and adjudication procedures will be established before enrollment as specified in the protocol.
Time frame: From pacemaker implantation through 24 months after implantation (cumulative event count).
Additional Cardiac Interventions
Number of additional cardiac interventions during follow-up. The indication, date, effects on LVEF or the pacing system, lead changes, and subsequent management will be recorded. Medically necessary interventions are permitted in either study arm.
Time frame: From pacemaker implantation through 24 months after implantation (cumulative event count).
Device-, Lead-, and Procedure-Related Complications
Number of device-, lead-, and procedure-related complications. Events include implantation complications and lead or device problems such as infection, bleeding, pneumothorax, perforation or tamponade, lead dislodgement or fracture, insulation failure, and failure to capture or sense. Major events and relatedness will be reviewed by the Clinical Events Adjudication Committee.
Time frame: From pacemaker implantation through 24 months after implantation (cumulative event count).
Repeat Pacing Procedures, Lead Revisions or Replacements, and System Upgrades
Number of repeat procedures involving the pacing system, including lead revision or replacement and system upgrade. Procedure type, indication, date, and resulting changes to the pacing system will be documented. Events will be reviewed by the Clinical Events Adjudication Committee.
Time frame: From pacemaker implantation through 24 months after implantation (cumulative event count).
Immediate Implantation Success
Successful implantation of the allocated pacing strategy, reported as the number and percentage of participants meeting the arm-specific technical success criteria. For CSP, assessment includes electrophysiological evidence of conduction-system capture, sensing, capture threshold, and impedance; RVP criteria are specified separately. Numerical thresholds and mandatory tests will be prospectively approved in the electrophysiology operational appendix before first enrollment.
Time frame: During the index implantation procedure
Pacing-System Function
Device or lead failures identified during clinical follow-up, device interrogation, or remote monitoring, including failure to capture or sense. Failures and subsequent management will be documented and relevant events reviewed by the Clinical Events Adjudication Committee.
Time frame: From implantation through 24 months
Implantation Procedure Duration
Duration of the index pacemaker implantation procedure, measured in minutes, compared between pacing strategies.
Time frame: During the index pacemaker implantation procedure.
Length of Hospital Stay
Duration of the hospital stay associated with the index pacemaker implantation, measured in days.
Time frame: Periprocedural (assessed at discharge from the hospitalization for pacemaker implantation).
Healthcare Resource Use
Healthcare resources used for implantation and follow-up, including staff time, equipment, diagnostic tests, and clinical visits. Resource categories will be recorded separately rather than combined into an unvalidated score. Detailed resource definitions and analysis procedures will be finalized in the operational procedures and statistical analysis plan.
Time frame: Day 1 (pacemaker implantation) through 24 months after implantation.
Left Ventricular Ejection Fraction at 12 Months
Left ventricular ejection fraction (LVEF), expressed as a percentage and measured by echocardiography at 12 months after implantation. The 12-month comparison is exploratory; the prespecified primary comparison is at 24 months.
Time frame: 12 months after implantation
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Dec 2029, 36 months later.
Of 44 interventional studies with no phase under Atrioventricular Block, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 36 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.